Clinical Trials Logo

Filter by:
NCT ID: NCT03563885 Terminated - Obesity Clinical Trials

Glucose Uptake in Metabolic Tissues After Bariatric Surgery

GU
Start date: October 1, 2018
Phase: N/A
Study type: Interventional

The goal of this study is to provide a comprehensive evaluation of whole-body and tissue-specific glucose metabolism after consuming a mixed meal in lean people and people with obesity, before and after 20-35% weight loss induced by Roux-en-Y gastric bypass or sleeve gastrectomy surgery.

NCT ID: NCT03563365 Terminated - Acne Vulgaris Clinical Trials

The Functional and Emotional Benefits of Replenix Power of Three With Resveratrol

Start date: June 4, 2018
Phase: Phase 4
Study type: Interventional

A Randomized, Investigator Blinded, Single Site, Three Arm Clinical Study to Assess the Functional and Emotional Benefits of Replenix Power of Three Cream with Resveratrol , Replenix Power of Three Cream with Resveratrol with Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, utilized to treat subjects with Facial Acne Vulgaris

NCT ID: NCT03563222 Terminated - Malnutrition, Child Clinical Trials

Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age

Start date: December 18, 2019
Phase: Phase 4
Study type: Interventional

Evaluate the safety and efficacy of Smoflipid compared to standard of care lipid emulsion Intralipid 20% administered via a central vein in pediatric patients 3 months to 16 years of age who require parenteral nutrition for at least 90 days and up to 1 year.

NCT ID: NCT03562949 Terminated - Asthma Clinical Trials

A BE Study to Compare Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg and QVAR® 40 mcg, Inhalation Aerosol

Start date: December 6, 2018
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety profiles of Beclomethasone dipropionate Inhalation Aerosol, 40 mcg (test product) and QVAR 40 mcg (beclomethasone dipropionate HFA), Inhalation Aerosol (reference product) and to demonstrate that the efficacy of the 2 active products is superior to that of placebo in the treatment of subjects with asthma.

NCT ID: NCT03562767 Terminated - Clinical trials for Diabetes Mellitus, Type 2

Cognitive Behavioral Therapy for African Americans With Uncontrolled Type-2 Diabetes

Start date: December 5, 2018
Phase: N/A
Study type: Interventional

The main purpose of the study is to assess the feasibility and acceptability of a Culturally-Tailored Cognitive Behavior intervention (CT-CB) for African American patients with uncontrolled Type 2 diabetes. After the baseline visit subjects will be randomly assigned to undergo a six session group-based or web-based behavioral intervention (CT-CB) program or to general education (usual care). The intervention duration is 12 weeks.

NCT ID: NCT03562702 Terminated - Dehydration Clinical Trials

Comparing Speedlyte and IV Rehydration Treating Children With Gastroenteritis in a Pediatric Emergency Department (ED)

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

To compare length of stay (LOS) of pediatric patients in a pediatric emergency room presenting with Gastroenteritis treated with IV rehydration versus oral Speedlyte rehydration.

NCT ID: NCT03562507 Terminated - Clinical trials for Renal Cell Carcinoma, Metastatic

Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

ERICA
Start date: April 11, 2019
Phase: Phase 2
Study type: Interventional

The objective of the trial is to determine the clinical efficacy of ESK981 in combination with nivolumab therapy in patients with metastatic renal cell carcinoma (RCC).

NCT ID: NCT03562416 Terminated - Clinical trials for Idiopathic Pulmonary Fibrosis

Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects

Start date: July 5, 2019
Phase: Phase 2
Study type: Interventional

The aim of this study is to assess the utility of nintedanib therapy in addition to usual transplant care in single lung transplant recipients with idiopathic pulmonary fibrosis (IPF). The investigators hypothesize that in IPF subjects who undergo single lung transplantation the administration of nintedanib 150 mg twice daily in addition to usual transplant care will result in better preservation of lung function at 24 months.

NCT ID: NCT03562247 Terminated - Clinical trials for Idiopathic Pulmonary Fibrosis

Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF)

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

Numerous studies show that remote monitoring and/or telenursing improves outcomes for patients especially those with chronic diseases. It is proposed that structured telenursing with non-invasive home monitoring of forced vital capacity and oxygen saturation in newly diagnosed patients with IPF will decrease hospitalizations for respiratory illness, increase compliance with therapies, and ultimately increase quality of life.

NCT ID: NCT03561090 Terminated - Clinical trials for Gastroesophageal Reflux Disease (GERD)

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Start date: June 20, 2018
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standard-dose PPIs.